Descripción de la empresa
AEON Biopharma, Inc. operates as a clinical stage biopharmaceutical company dedicated to the development of botulinum toxins for the treatment of debilitating medical conditions. Within the broader healthcare sector, the firm specifically functions in the biotechnology industry, focusing on advancing therapeutic modalities such as the ABP-450 (prabotulinumtoxinA) injection for conditions including cervical dystonia. The company currently holds a market capitalization of $23.72M, while its annual revenue and employee count are not disclosed in the available financial data. This limited market capitalization indicates that the company remains in an early-stage development phase where capital markets value its potential pipeline rather than established commercial sales or a large workforce.
Salud financiera
The reported net income over the trailing twelve months stands at -$39,222,000, while EBITDA is recorded at -$16,224,000; the significant disparity between these negative figures reveals a substantial cost structure burdened by high operating expenses or non-operating charges that exceed earnings before interest, taxes, depreciation, and amortization. Additionally, the trailing twelve-month revenue is not available, yet the free cash flow is reported at -$10,995,750, indicating a current consumption of cash reserves that limits immediate financial flexibility for expansion or acquisitions. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a metric that suggests the company has not yet generated positive gross profitability or is unable to calculate these ratios due to the absence of revenue data. On the balance sheet, the company holds $3.01M in cash against $35.74M in debt, resulting in a negative debt-to-equity ratio environment that reflects a highly leveraged position relative to its equity base. Furthermore, the current ratio is 0.49, a figure below unity that signals potential short-term liquidity challenges as current assets are insufficient to cover current liabilities without external financing. Finally, the return on equity is not available, while the return on assets is -234.2%, a metric that indicates management is currently generating negative returns on the total asset base employed in the business.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is listed as -1.36, implying that the market expects earnings to remain negative or that valuation models are adjusting for the company's current loss position. The price-to-book ratio stands at -0.21, indicating that the market values the company at a negative premium relative to its book value, a scenario common for distressed or pre-revenue biotechnology firms with significant liabilities. The price-to-sales ratio is not available, and the enterprise value-to-EBITDA is -3.48, suggesting that traditional multiple-based valuations are distorted by the company's negative cash flows and lack of established sales revenue. Regarding price volatility, the 52-week high is $1.45 and the 52-week low is $0.38, meaning the stock is trading at a point that reflects significant downside from its peak performance over the last year. The beta value is 0.73, which indicates that the stock price is less volatile than the broader market index and moves with a lower degree of sensitivity to general market fluctuations.
Growth & Income
The year-over-year revenue growth and earnings growth rates are both not available, preventing a direct comparison of growth rates between top-line expansion and bottom-line profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash flows are reinvested into research and development rather than distributed to shareholders. Since the company does not distribute dividends, the financial strategy focuses entirely on capitalizing the clinical pipeline and securing future funding to advance the ABP-450 product candidates through regulatory approval processes. The overall growth and income profile is characterized by a complete reliance on future potential rather than current cash generation or dividend income streams, typical for clinical-stage biopharmaceutical entities.